Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
Portfolio Pulse from Lara Goldstein
Cybin Inc. (NYSE:CYBN) and psychedelic therapy education organization Fluence have partnered to streamline and scale Cybin's EMBARK facilitator training program for a global Phase 3 trial of deuterated psilocybin analog CYB003 for major depressive disorder treatment. Fluence will assist Cybin in selecting and training facilitators for the trial, produce additional video content, and offer both real-time and self-paced training.
September 26, 2023 | 7:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has partnered with Fluence to streamline and scale its EMBARK facilitator training program for a global Phase 3 trial of CYB003. This partnership could potentially enhance the success of the trial and the eventual commercialization of CYB003.
The partnership with Fluence will help Cybin in selecting and training facilitators for its planned Phase 3 trial, which is crucial for the success of the trial. Successful trials could lead to the eventual commercialization of CYB003, which could potentially boost Cybin's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100